Study to Nivolumab Following Preoperative Chemoradiotherapy
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II, open-label, single-arm, multicenter study to investigate the safety,
efficacy, and proof of concept (POC) of monotherapy with nivolumab, an anti-PD-1 antibody
drug, as a sequential therapy following chemoradiotherapy (CRT) with capecitabine and
subsequent surgical therapy in patients with locally advanced resectable rectal cancer.